GLAXO — GlaxoSmithKline Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- IN₹317.00bn
- IN₹300.00bn
- IN₹32.52bn
- 96
- 11
- 91
- 79
2019 March 31st | R2020 March 31st | R2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 11,478 | 10,618 | 11,372 | 28,309 | 16,541 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,288 | 1,907 | 2,975 | 3,052 | 3,419 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 20,095 | 17,749 | 22,026 | 37,080 | 24,943 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 13,671 | 8,271 | 3,554 | 3,254 | 3,151 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 39,113 | 31,332 | 31,146 | 46,333 | 33,266 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 14,543 | 10,220 | 13,546 | 16,984 | 13,264 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 17,715 | 13,126 | 16,364 | 19,703 | 15,853 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 21,398 | 18,206 | 14,783 | 26,630 | 17,413 |
Total Liabilities & Shareholders' Equity | 39,113 | 31,332 | 31,146 | 46,333 | 33,266 |
Total Common Shares Outstanding |